Olga Alexeeva

launching therapeutics and precision tests #ctDNA #MRD #oncology

[Olga Alexeeva @OlgaAlexeeva16]

Looks eons better than the cyber truck

[Reuters @Reuters]

Ferrari shares plunged by more than 8% as investors and critics reacted coolly to the Italian luxury sports carmaker's new Luce electric car, questioning whether it remained true to the brand's identity https://t.co/NC2DVg80Di

[Personalis, Inc. @PersonalisInc]

"The ultimate goal is that all decisions made in oncology will be somehow guided by ctDNA" 🎯

Dr. Barcenas discusses the future of ultrasensitive MRD testing in breast cancer—from treatment de-escalation trials to FDA surrogate endpoints.

The future of precision oncology is here. Watch 👇
#ctDNA #LiquidBiopsy #BreastCancer

[Personalis, Inc. @PersonalisInc]

"We made the right decision" ✓

Dr. Barcenas on why Personalis was the right partner for their HER2+ breast cancer research:

🤝 High sample capture
🤝 Proven analytic validity
🤝 Workflow
🤝 ctDNA clearance linked to outcomes

When precious samples are on the line, the ultrasensitive ctDNA test matters.

#PrecisionOncology #BreastCancer #ctDNA #ClinicalResearch #Innovation

[DrKatyMoore @DrKatyMoore]

#ASCO25 ctDNA from the CALLA Study of cervical cancer take aways:
1) baseline detection of ctDNA for pts with local regionally advanced disease is 99%
2) Among pts on the durva arm, at cycle 3, 38% of pts had "+" ctDNA and by cycle 6 this dropped to 23%. (figure 1)
3) pts with "-" ctDNA looked like they did NOT benefit from durva but in the ctDNA "+" there is a signal of benefit (figure 2 and 3)
4) ctDNA "+" at cycle 3 was associated with recurrence in 68% of patients with a median lead time of 164 days (figure 4)

My question: If I know you are ctDNA+ at cycle 3 (?or 6 6) should we add additional therapy aka OUTBACK or a new ADC at that point? or wait until clinical progression? What changes OS? What changes patient QoL?

[Nicole Casasanta, MD @ncasasanta]

Lots of buzz around @theTBCRC 040 PREDICT-DNA trial presented by Dr. Natasha Hunter 🐝 ➰
➡️ Among HER2+ & TNBC pts receiving NAT ctDNA may be may be a better biomarker than pCR for longterm outcomes 🧬
🔸54% ctDNA <100 ppm after NAT
🔸NPV for residual disease 60%
#ASCO2025

[Nancy Lin, MD @nlinmd]

TBCRC 040 (PREDICT-DNA trial): Dr. Natasha Hunter presents -
-HER2+ or TN pts with MRD assay after NAT and pre surgery
-in TNBC, ctDNA MRD status distinguished between those with RD who had excellent vs poor prognosis
@hthrparsons @TheTBCRC @awolff @benhopark

[Susan G. Komen @SusanGKomen]

#ASCO25: PREDICT-DNA study shows ctDNA testing after neoadjuvant chemo can identify HER2+/TNBC patients at highest recurrence risk - particularly important for TNBC cases. Could help identify who needs more treatment post-surgery. @UWMedicine @fredhutch

[Personalis, Inc. @PersonalisInc]

Day 2 at #ASCO25! 🎬 Take a look inside our booth #31137 where we're showcasing the power of ultrasensitive ctDNA detection with NeXT Personal®.

Still time to catch our presentations today & tomorrow: 🗣️ TODAY PM at Arie Crown Theatre: Dr. Natasha Hunter - initial data from PREDICT-DNA breast cancer trial
🗣️ TOMORROW AM at S100a: Dr. Jyoti Mayadev - CALLA trial in cervical cancer
📋 TOMORROW AM-12:00 PM in Poster Hall A (552/145): Dr. Luc Cabel - TNBC post-NAC findings
📋 TOMORROW -4:30 PM in Poster Hall A (2561/208): Dr Charles Abbott - Immunotherapy predictors in advanced cancer

Stop by booth #31137 to partner
#PrecisionOncology #ctDNA #MRD #RecurrenceDetection #breastcancer #cervicalcancer #immunotherapy @OlgaAlexeeva16

[Personalis, Inc. @PersonalisInc]

⏯️ Check out this new video showing the ability of NeXT Personal® to consistently achieve highly sensitive limits of detection (LOD) across a large number of patient samples across many solid tumor types, including samples of poor quality:

• NeXT Personal demonstrated a median LOD of 1.9 parts per million (PPM) with a range of 1.6-2.8 PPM across this real world data cohort (4,232 plasma timepoints across 1,796 patients)
• 40.9% of all MRD positive samples were detected in the ultrasensitive range (≤100 PPM), and 86.8% of molecular recurrence detections were in the ultrasensitive range
• Median ctDNA level for first molecular recurrence detection was 12 PPM, underscoring the importance of ultrasensitive testing for early recurrence detection

#PrecisionOncology #ctDNA #SensitivityMatters #MRD #LiquidBiopsy #CancerTesting

[Personalis, Inc. @PersonalisInc]

🚨 BIG NEWS! 🚨 A talk by one of our collaborators was hand-selected for an additional moderated session at #AACR25!

@emma_titmuss shared a preview of #VICTORI study (#ColorectalCancer #MRD) during a press conference: https://t.co/omvTMWeNf6.

You can see Emma present the full results later today at 3:35 PM in Room S105 - McCormick Place South.

Make sure to also check out a presentation by Prof. @CharlesSwanton who will share results from #TRACERx study at 12:35 PM in the Grand Ballroom.

#PrecisionOncology #Biomarkers #LiquidBiopsy #ctDNA #WGS #ClinicalTrials #LungCancer

(Not affiliated with or endorsed by AACR)

[Personalis, Inc. @PersonalisInc]

Read on for patient vignettes below…

Transforming bladder cancer immunotherapy-monitoring treatment decisions through molecular insights: Dr. Alan Tan, MD's (@alantanmd) recent presentation showcases how ctDNA analysis with our @TempusAI /Personalis xM (NeXT Personal® Dx) assay provided predictive information for his patients.

Patient Vignette 1: ctDNA Kinetics were Predictive

• Patient with muscle-invasive bladder cancer showed initial ctDNA decrease during neoadjuvant therapy (from ~1000 to 23 parts per million)
• Critical finding: ctDNA did not clear on IO (immunotherapy) neoadjuvant treatment with enfortumab vedotin and pembrolizumab (EV/P), with the low level of ctDNA detection in the ultrasensitive range. The patient then showed an upward trend in ctDNA pre-cystectomy.
• Surgical outcome: Surgery confirmed lymph node involvement and ovarian spread

[Personalis, Inc. @PersonalisInc]

Our groundbreaking data in #BreastCancer was just published in the ESMO Annals of Oncology! (@myESMO).

In collaboration with @royalmarsdenNHS and @ICR_London (@igmurillas), this study reports on the performance of NeXT Personal® in a cohort of 78 patients with breast cancer (all subtypes):

- NeXT Personal detected very small traces of cancer recurrence in the blood a median of ~15 months ahead of scans
- The test detected 100% of the patients that had breast cancer recurrence
- 100% of patients with undetectable post-treatment ctDNA remained recurrence-free during a median follow up period of 76 months.
- NeXT Personal showed high sensitivity for detecting early-stage breast cancer with ~39% of all detections occurring in the ultra-sensitive range below 100 PPM

Discover more https://t.co/PGDJNDYCFA

#PrecisionOncology #LiquidBiopsy

[Olga Alexeeva @OlgaAlexeeva16]

RT @PersonalisInc: We recently attended #ASCOGI and presented data in #ColorectalCancer, including results from the VICTORI study using NeX…

[Olga Alexeeva @OlgaAlexeeva16]

@KUTX please play some positive beats on this gray day!

[Personalis, Inc. @PersonalisInc]

We’re here along with our collaborators at ASCO #GI25 in the Moscone Center in downtown San Francisco!

We’re excited to highlight a few posters with data in #ColorectalCancer, including results from the VICTORI study using NeXT Personal® in collaboration with @BCCancer (Dr @jonathanloree and Dr Joao Paulo Solar Vasconcelos).

Please stop by and visit our poster (abstract 275/L9) on Saturday, January 25th on level 1, West Hall from 7:00AM to 8:00AM PST.

Our collaborators from the @MayoClinic will also be presenting results in colorectal cancer using ImmunoID NeXT® (abstract 270/L4) in level 1, West Hall from 7:00AM to 8:00AM PST on January 25th.

Look forward to seeing you there!

https://t.co/dwZcMboT7P

[Personalis, Inc. @PersonalisInc]

Today, we published new results from the #TRACERx lung cancer study in Nature Medicine: https://t.co/xzwnFt27mK

In collaboration with @CharlesSwanton and his colleagues at @TheCrick and @uclcancer, this groundbreaking study highlights advancements in #LungCancer detection using NeXT Personal®.

Key highlights:

- NeXT Personal test showed high sensitivity for detecting early-stage I-III NSCLC pre-operatively: 100% of non-adenocarcinomas and 81% of lung adenocarcinomas (LUAD)
- Early-stage LUAD patients who tested negative for #ctDNA with NeXT Personal prior to surgery exhibited a 100% 5-year overall survival rate; patients testing positive had a high overall risk of relapse during that same period
- Patients who tested positive for very low traces of cancer (<80 PPM) still had a high risk of recurrence, suggesting the importance of ultra-sensitive #MRDTesting with NeXT Personal

[Personalis, Inc. @PersonalisInc]

Our team is here at #SITC24 in Houston!
Swing by our booth (801) to learn more about our cutting-edge minimal residual disease (MRD) monitoring assay for #ClinicalTrials and other innovations for #PrecisionOncology.
We look forward to seeing you here!
#ImmunoTherapy #Oncology #CancerResearch #LiquidBiopsy @sitcancer

[Personalis, Inc. @PersonalisInc]

For patients with cancer, the earlier you track the better prepared you can be.

Watch the video below (@OlgaAlexeeva16) to discover how NeXT Personal® is able to detect cancer recurrence earlier through the identification of circulating tumor DNA (ctDNA).

#PrecisionOncology #LiquidBiopsy #MRD #ctDNA

[Olga Alexeeva @OlgaAlexeeva16]

Join me at #SITC24 in Houston! 🌟 Showcasing @PersonalisInc's advanced MRD monitoring assay for clinical trials. Stop by booth 801 to chat! ✨

[Personalis, Inc. @PersonalisInc]

“We worked tirelessly with engineers, architects, and lab developers to build what was the best possible laboratory…”

Hear from Personalis leaders as we take you on a journey through our state-of-the-art facility. See the full video: https://t.co/LDxL52lf4l.

#PrecisionOncology